Kevin J Renfree1, Steven J Hattrup, Yu-Hui H Chang. 1. Department of Orthopedics, Mayo Clinic Hospital, Phoenix, AZ, USA; Division of Plastic and Reconstructive Surgery, Mayo Clinic Hospital, Phoenix, AZ, USA. Electronic address: renfree.kevin@mayo.edu.
Abstract
BACKGROUND: Reverse shoulder arthroplasty provides satisfactory outcomes, but its cost-effectiveness is unproven. We prospectively analyzed outcomes and costs for primary reverse shoulder arthroplasty. METHODS: Thirty serial patients (16 women and 14 men; mean age, 74.1 years [range, 61.1-87.3 years]) with rotator cuff arthropathy had active motion recorded and completed function tests (visual pain analog scale; Simple Shoulder Test; American Shoulder and Elbow Surgeons Shoulder Outcome score; EuroQol; and Short Form-36 Health Survey) preoperatively and postoperatively at 1 and 2 years. Costs included professional fees, operating room and supply costs, and hospital care. Changes were compared by the Wilcoxon signed rank test, and quality-adjusted life-years were calculated preoperatively and postoperatively. RESULTS: Twenty-seven patients completed the study. Clinical and functional outcomes demonstrated significant improvement (P < .05). Significantly improved (P < .05) Short Form-36 subgroups included physical functioning, role limitations due to physical health, bodily pain, vitality, and physical composite score. EuroQol dimensions of usual activities and pain/discomfort improved significantly (P < .05). Calculations with the SF-6D showed that median QALYs improved from 6.56 preoperatively to 7.43 at 1-year follow-up (P <.09) and from 6.56 preoperatively to 7.58 at 2-year follow-up (P <.003). The increase in QALYs calculated from the EQ-5D was somewhat greater, changing from 6.21 preoperatively to 7.69 at 1-year follow-up (P <.0001) and from 6.13 to 8.10 at 2-year follow-up (P <.04). Mean cost was $21,536. Cost utility at 2 years was $26,920/quality-adjusted life-year by the Short Form 6 Dimensions and $16,747/quality-adjusted life-year by the EuroQol. CONCLUSION: EuroQol and Short Form-36 results demonstrated modestly cost-effective (<$50,000/quality-adjusted life-year) improvement for cuff tear arthropathy patients after primary reverse shoulder arthroplasty. LEVEL OF EVIDENCE: Level II, economic and decision analysis.
BACKGROUND: Reverse shoulder arthroplasty provides satisfactory outcomes, but its cost-effectiveness is unproven. We prospectively analyzed outcomes and costs for primary reverse shoulder arthroplasty. METHODS: Thirty serial patients (16 women and 14 men; mean age, 74.1 years [range, 61.1-87.3 years]) with rotator cuff arthropathy had active motion recorded and completed function tests (visual pain analog scale; Simple Shoulder Test; American Shoulder and Elbow Surgeons Shoulder Outcome score; EuroQol; and Short Form-36 Health Survey) preoperatively and postoperatively at 1 and 2 years. Costs included professional fees, operating room and supply costs, and hospital care. Changes were compared by the Wilcoxon signed rank test, and quality-adjusted life-years were calculated preoperatively and postoperatively. RESULTS: Twenty-seven patients completed the study. Clinical and functional outcomes demonstrated significant improvement (P < .05). Significantly improved (P < .05) Short Form-36 subgroups included physical functioning, role limitations due to physical health, bodily pain, vitality, and physical composite score. EuroQol dimensions of usual activities and pain/discomfort improved significantly (P < .05). Calculations with the SF-6D showed that median QALYs improved from 6.56 preoperatively to 7.43 at 1-year follow-up (P <.09) and from 6.56 preoperatively to 7.58 at 2-year follow-up (P <.003). The increase in QALYs calculated from the EQ-5D was somewhat greater, changing from 6.21 preoperatively to 7.69 at 1-year follow-up (P <.0001) and from 6.13 to 8.10 at 2-year follow-up (P <.04). Mean cost was $21,536. Cost utility at 2 years was $26,920/quality-adjusted life-year by the Short Form 6 Dimensions and $16,747/quality-adjusted life-year by the EuroQol. CONCLUSION: EuroQol and Short Form-36 results demonstrated modestly cost-effective (<$50,000/quality-adjusted life-year) improvement for cuff tear arthropathypatients after primary reverse shoulder arthroplasty. LEVEL OF EVIDENCE: Level II, economic and decision analysis.
Authors: Jacques Guery; Luc Favard; François Sirveaux; Didier Oudet; Daniel Mole; Gilles Walch Journal: J Bone Joint Surg Am Date: 2006-08 Impact factor: 5.284
Authors: H Osnes-Ringen; M K Kvamme; I S Kristiansen; M Thingstad; J E Henriksen; T K Kvien; H Dagfinrud Journal: Scand J Rheumatol Date: 2011-01-17 Impact factor: 3.641
Authors: Stephen G Thon; Adam J Seidl; Jonathan T Bravman; Eric C McCarty; Felix H Savoie; Rachel M Frank Journal: Curr Rev Musculoskelet Med Date: 2020-02
Authors: Jeremy S Somerson; Moni B Neradilek; Jason E Hsu; Benjamin C Service; Albert O Gee; Frederick A Matsen Journal: Int Orthop Date: 2017-03-28 Impact factor: 3.075
Authors: Jay M Levin; John Wickman; Alexander L Lazarides; Daniel J Cunningham; Daniel E Goltz; Richard C Mather; Oke Anakwenze; Tally E Lassiter; Christopher S Klifto Journal: Clin Orthop Relat Res Date: 2022-01-11 Impact factor: 4.755
Authors: Hassaan Abdel Khalik; Brittany Humphries; Michael Zoratti; Daniel Axelrod; Colin Kruse; Bill Ristevski; Krishan Rajaratnam; Michael Gardner; Jean-Éric Tarride; Herman Johal Journal: Clin Orthop Relat Res Date: 2022-05-04 Impact factor: 4.755
Authors: E Bailey Terhune; Peter C Cannamela; Jared S Johnson; Charles D Saad; John Barnes; Janette Silbernagel; Thomas Faciszewski; Kevin G Shea Journal: Orthop J Sports Med Date: 2016-12-16